Chapter 14 — Key Takeaways
The core claims
1. Growth hormone is 191 amino acids from the anterior pituitary, and it sits in an axis with both an accelerator and a brake. GHRH stimulates release; somatostatin inhibits it. Most endocrine axes have only an accelerator plus end-product feedback. This one has a dedicated inhibitory hormone too, which means an intervention can work by pressing the accelerator or by lifting the brake.
2. Secretion is pulsatile, so a single measurement is nearly useless. Bursts, mostly nocturnal, near-undetectable in between. Diagnosis uses IGF-1 — stable because it is largely protein-bound, and therefore a running average of recent exposure — or dynamic stimulation testing. A clinic that diagnoses deficiency from one random growth hormone level has told you about itself.
3. Growth hormone acts directly and through IGF-1, and the two are not interchangeable. Direct: lipolysis, insulin antagonism, sodium and water retention, nitrogen retention. Via IGF-1: growth-plate bone growth, cell proliferation, inhibition of apoptosis, tissue maintenance. They can even oppose each other on glucose.
4. Growth hormone raises blood glucose. It is a counter-regulatory hormone. This one fact explains most of its risk profile and essentially all of the metabolic disease in acromegaly, and it is the most consistently underweighted point in consumer discussion.
5. Deficiency is real, diagnosable, and treatable — and that is a replacement. Children grow. Adults improve on body composition, bone density, lipids, and quality of life. Replacement of an absent signal predicts durable benefit, and that is what the literature shows.
6. The age-related decline is real; its meaning is contested. Growth hormone falls with age and the resulting picture resembles adult deficiency. But aging changes everything at once, body fat suppresses growth hormone (so the arrow may point the other way), a decline is not an absence, and reduced growth signaling extends lifespan in model organisms. Do not resolve this. The field has not.
7. Rudman 1990 is the founding citation, and it must be quoted whole. Twelve men over 60, six months of growth hormone versus untreated controls: increased lean mass and decreased fat mass. It did not measure strength, function, or long-term safety. The finding is real and replicates. The inference built on it is what failed.
8. Later randomized trials found the surrogate and not the outcome. Body composition changed; strength and function did not convincingly improve; edema, arthralgia, carpal tunnel, gynecomastia, and glucose impairment were more common in treated participants.
9. The cancer question is open, in both directions. Mechanism points the wrong way (proliferation, apoptosis inhibition). Observational IGF-1 associations exist. Confounding is substantial and no causal claim is established. Not knowing is not the same as knowing it is fine.
10. Acromegaly is the natural experiment, and it establishes direction, not magnitude. Decades of excess produce arthropathy, cardiomyopathy, diabetes, sleep apnea, colonic polyps, and reduced life expectancy — with mortality improving when the excess is controlled, which is what makes the causal reading credible. It does not predict what happens at lower exposures. Nothing does.
11. One molecule, two ratings, no contradiction. The claim carries the rating. Strip out the population and the two rows conflict; leave it in and they are two facts.
The ratings
| Claim (population + endpoint) | Rating | One-line reason |
|---|---|---|
| GH replacement in documented GH deficiency (children: growth; adults: body composition, bone density, lipids, quality of life) | ✅ | Decades of controlled trials, consistent, approved everywhere, characterized safety profile, monitored |
| GH in healthy adults without deficiency, for anti-aging or improved function | ❌ | Effect shown is a surrogate; strength and function did not follow; long-term safety unestablished; acromegaly gives real reason for concern |
Both date-stamped as of this writing, 2026.
What would move the ❌: an adequately powered, randomized, blinded, placebo-controlled trial in healthy older adults, running years not months, with prespecified functional and clinical endpoints — strength, gait speed, disability, falls, fractures, hospitalization, independent living, cardiovascular events, malignancy, mortality — showing benefit that outweighs harms.
Read the ❌ correctly: it describes the evidence for a claim. It is not the statement that growth hormone does nothing. Rudman measured real changes and they replicate.
Key numbers
| Growth hormone length | 191 amino acids, single chain |
| Growth hormone mass | ~22 kDa |
| IGF-1 length | ~70 amino acids |
| Age-related decline | ~14% per decade after ~30 (approximate) |
| Rudman study | 12 men, over 60, 6 months, untreated controls, 1990 |
| Cadaver GH distribution halted | 1985 (CJD via prions) |
| Recombinant GH available | mid-1980s — removed the supply constraint |
| Compounds entering human trials that reach approval | roughly 1 in 10 |
Key terms
Growth hormone · somatotropin · somatotroph · GHRH · somatostatin · IGF-1 · IGFBP · pulsatile secretion · dynamic stimulation testing · growth hormone deficiency · adult growth hormone deficiency · somatopause · surrogate endpoint · replacement versus override · lipolysis · insulin antagonism (counter-regulatory) · apoptosis · acromegaly · gigantism · Laron syndrome · recombinant
What you can now evaluate
- Whether a "hormone panel" is a diagnostic workup or a sales funnel — from the testing alone
- Whether a citation of Rudman 1990 is inside or outside the study's scope
- Whether a marketing phrase is using the replacement frame on an override population
- Whether a risk claim about growth hormone is overstated, understated, or correctly hedged
- Why "restoring youthful levels" is a choice of comparison group presented as a clinical finding
- How to extract a direction of risk from a natural experiment without extrapolating a magnitude
- How to hold ✅ and ❌ for one molecule and explain to someone else why both are right
The one-sentence version
Growth hormone plainly does something — it changes body composition, and that has been replicated since 1990 — but changing a surrogate is not the same as improving strength, function, or health, which is why replacing it in documented deficiency is ✅ and adding it to a healthy adult for anti-aging is ❌.
Next
Chapter 15 — Growth Hormone Secretagogues. If injecting growth hormone is expensive, legally restricted, and suppresses your own production, the obvious move is to make the pituitary produce more of its own. That is sermorelin, tesamorelin, the GHRP family, ipamorelin, and MK-677 — and it is a genuinely better idea in several specific respects. Whether "more physiological" translates into "more effective" or "safer" is a different question, and the axis diagram in §14.1 already contains most of what you need to anticipate the answer.